8-K: Arbutus Biopharma Announces Imdusiran Data to be Highlighted at The Liver Meeting 2024

Arbutus Biopharma will present clinical data on its RNAi therapeutic, imdusiran, at the AASLD Liver Meeting in November, including two late-breaking posters from Phase 2a trials.

Summary

• Arbutus Biopharma has announced that clinical data for imdusiran, an RNAi therapeutic, will be featured in four poster presentations at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting 2024.
• The presentations will include two late-breaking posters showcasing data from the IM-PROVE I and IM-PROVE II Phase 2a clinical trials.
• One presentation will focus on soluble immune biomarker profiling in chronic hepatitis B subjects treated with imdusiran and pegylated interferon, revealing phases of immune activation.
• Another presentation will highlight that the imdusiran target site is highly conserved in chronic hepatitis B subjects, with in vitro testing confirming the drug's activity against tested variants.
• Imdusiran has demonstrated clinical activity against HBV genotypes A-E.
• The company plans to make the poster presentations available on its website on November 15, 2024.
• Imdusiran is designed to reduce all HBV viral proteins and antigens, including hepatitis B surface antigen, and has shown meaningful reductions in hepatitis B surface antigen and hepatitis B DNA in clinical trials.
• Arbutus is also developing an oral PD-L1 inhibitor, AB-101, which is currently in a Phase 1a/1b clinical trial.

Sentiment

Score: 7

Explanation: The document is positive due to the presentation of clinical data at a major conference and the progress of the imdusiran program. However, it is not overly bullish as it is still early in the clinical development process and there are inherent risks.

Positives

• The acceptance of four abstracts for presentation at a major liver disease conference highlights the progress of imdusiran.
• The late-breaking poster presentations suggest significant new data from the Phase 2a trials.
• The biomarker analysis shows a clear immune response to imdusiran treatment.
• The high conservation of the imdusiran target site and its activity against variants is a positive sign for its efficacy.
• Imdusiran has shown clinical activity against multiple HBV genotypes.
• The company has a pipeline of internally developed compounds, including an RNAi therapeutic and an oral PD-L1 inhibitor.

Risks

• Clinical trials may be more costly or take longer to complete than anticipated.
• The company may change its strategy regarding its product candidates and clinical development activities.
• Arbutus may not receive the necessary regulatory approvals for the clinical development of its products.
• Economic and market conditions may worsen, impacting the company's operations.
• Market shifts may require a change in strategic focus.

Future Outlook

The company anticipates further development of its product candidates and expects to release data from clinical trials. They are focused on developing a functional cure for chronic hepatitis B.

Management Comments

• Arbutus believes the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses.

Industry Context

The announcement is relevant to the broader industry trend of developing novel therapeutics for chronic hepatitis B, a significant unmet medical need. The focus on RNAi technology and immune modulation aligns with current research directions in the field.

Comparison to Industry Standards

• Gilead Sciences is a major player in the HBV space with drugs like Vemlidy, but Arbutus is focusing on a functional cure with a different approach using RNAi and immune modulation.
• Other companies like Vir Biotechnology are also exploring novel therapies for HBV, including antibodies and T-cell therapies, but Arbutus's approach with imdusiran is unique.
• The Phase 2a trial data will be closely watched to see how it compares to other experimental therapies in terms of efficacy and safety.
• The focus on surface antigen reduction and immune response is a common goal in the field, but the specific mechanisms and results of imdusiran will be compared to other approaches.

Stakeholder Impact

• Shareholders will be interested in the clinical data presented at the conference.
• The results of the clinical trials could impact the company's valuation.
• Patients with chronic hepatitis B may benefit from the development of new therapies.
• The company's employees are involved in the research and development of these therapies.

Next Steps

• Arbutus will present the imdusiran data at the AASLD Liver Meeting 2024 from November 15-19, 2024.
• The company will make the poster presentations available on its website on November 15, 2024.
• Arbutus will continue the clinical development of imdusiran and AB-101.

Key Dates

Keywords

Imdusiran, RNAi, Hepatitis B, HBV, AASLD, Liver Meeting, Clinical Trials, Biomarkers, AB-729, AB-101, Phase 2a, Therapeutics